Content about Supreme Court of the United States

June 17, 2013

Patent settlements between brand and generic drug makers commonly referred to as "pay-for-delay" settlements are not necessarily against the law, the Supreme Court ruled Monday.

NEW YORK — Patent settlements between brand and generic drug makers commonly referred to as "pay-for-delay" settlements are not necessarily against the law, the Supreme Court ruled Monday.

March 25, 2013

The Supreme Court heard arguments Monday in a case that could determine the future of generic drugs in America.

NEW YORK — The Supreme Court heard arguments Monday in a case that could determine the future of generic drugs in America.

The case, Federal Trade Commission v. Actavis, marks the latest attempt by federal authorities to put an end to what they say are deals between branded and generic drug companies that delay release of generic drugs to consumers.

March 5, 2013

The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

NEW YORK — The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

The case, FTC v. Actavis, will go before the high court on March 25 and may decide the future of patent settlements between branded and generic drug companies. The Generic Pharmaceutical Association filed an amicus brief with the court last week defending the settlements as beneficial to consumers.

March 1, 2013

The Supreme Court will hear arguments later this month in a case that could determine the future of many patent settlements between brand and generic drug makers.

WASHINGTON — The Supreme Court will hear arguments later this month in a case that could determine the future of many patent settlements between brand and generic drug makers.

The high court will hear arguments in the case, Federal Trade Commission v. Actavis, on March 25. The case was originally titled FTC v. Watson, but has changed since Watson Pharmaceuticals changed its name following its acquisition of Swiss generic drug maker Actavis.

March 27, 2012

The Supreme Court on Tuesday morning heard arguments on whether the individual mandate portion of the Patient Protection and Affordable Care Act is constitutional.

WASHINGTON — The Supreme Court on Tuesday morning heard arguments on whether the individual mandate portion of the Patient Protection and Affordable Care Act is constitutional. The final decision, expected in June, could mean a swing between 15 million and 27 million Americans, along with their prescription and other healthcare needs, entering the insurance market in 2014, according to a recent study published by the Rand Corp.

March 26, 2012

The Ninth Circuit Court of Appeals ruled in favor of healthcare providers, denying a request by the California Department of Health Care Services to suspend a preliminary injunction that currently is preventing the implementation of Medi-Cal cuts.

ALEXANDRIA, Va. — The Ninth Circuit Court of Appeals ruled in favor of healthcare providers, denying a request by the California Department of Health Care Services to suspend a preliminary injunction that currently is preventing the implementation of Medi-Cal cuts.

March 26, 2012

The U.S. Supreme Court justices have gathered this week to discuss a potential legal issue surrounding President Obama's healthcare law.

WASHINGTON — The U.S. Supreme Court justices have gathered this week to discuss a potential legal issue surrounding President Obama's healthcare law.

February 24, 2012

The Supreme Court has sent a lawsuit challenging cuts to California's Medicaid program back to a lower court.

ALEXANDRIA, Va. — The Supreme Court has sent a lawsuit challenging cuts to California's Medicaid program back to a lower court.

The high court ruled 5-4 in the case of Douglas v. Independent Living Center of Southern California that healthcare providers could challenge Medicaid reimbursement cuts under the U.S. Constitution's supremacy clause. The decision returns the case to the Ninth Circuit Court of Appeals, which had originally ruled that the providers had standing to sue.

August 31, 2010

Eli Lilly's method-of-use patents for its osteoporosis drug were declared valid by a federal court...

August 29, 2010

Industry lobbyists last week weighed in on a Ninth Circuit ruling that allowed for a...

WASHINGTON Industry lobbyists last week weighed in on a Ninth Circuit ruling that allowed for a class action lawsuit to proceed against Matrixx Initiatives because that company failed to disclose adverse event reports to its shareholders.